IL94624A0 - Human monoclonal antibodies to hiv-1 mn qq120 - Google Patents

Human monoclonal antibodies to hiv-1 mn qq120

Info

Publication number
IL94624A0
IL94624A0 IL94624A IL9462490A IL94624A0 IL 94624 A0 IL94624 A0 IL 94624A0 IL 94624 A IL94624 A IL 94624A IL 9462490 A IL9462490 A IL 9462490A IL 94624 A0 IL94624 A0 IL 94624A0
Authority
IL
Israel
Prior art keywords
hiv
monoclonal antibodies
human monoclonal
human
antibodies
Prior art date
Application number
IL94624A
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Publication of IL94624A0 publication Critical patent/IL94624A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
IL94624A 1989-06-05 1990-06-05 Human monoclonal antibodies to hiv-1 mn qq120 IL94624A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36154189A 1989-06-05 1989-06-05
US43128189A 1989-11-03 1989-11-03

Publications (1)

Publication Number Publication Date
IL94624A0 true IL94624A0 (en) 1991-04-15

Family

ID=27001330

Family Applications (1)

Application Number Title Priority Date Filing Date
IL94624A IL94624A0 (en) 1989-06-05 1990-06-05 Human monoclonal antibodies to hiv-1 mn qq120

Country Status (7)

Country Link
EP (1) EP0478689A4 (en)
JP (1) JPH05506561A (en)
AU (1) AU6036690A (en)
CA (1) CA2058630A1 (en)
IL (1) IL94624A0 (en)
PT (1) PT94276A (en)
WO (1) WO1990015078A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2989862B2 (en) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 Monoclonal antibody
US5712373A (en) * 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
JPH06502539A (en) * 1990-10-26 1994-03-24 ザ・パブリック・ヘルス・リサーチ・インスティチュート・オブ・ザ・シティ・オブ・ニューヨーク・インコーポレーテッド Neutralizing human monoclonal antibody specific for the V3 loop and CD-4 binding site of HIV-1 GP120
IT1244529B (en) * 1991-01-30 1994-07-15 Ist Superiore Sanita SYNTHETIC PEPTIDES SUITABLE TO ENHANCE THE INFECTIVITY OF THE HIV-1 VIRUS
WO1993004090A1 (en) * 1991-08-22 1993-03-04 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
US5558865A (en) * 1991-08-22 1996-09-24 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
NZ251582A (en) * 1992-04-01 1997-07-27 Merck & Co Inc Recombinant human anti-hiv antibodies, methods for their cloning and expression and pharmaceutical compositions thereof
WO1994000151A1 (en) 1992-06-18 1994-01-06 Creagen, Inc. Combinatorial polypeptide antigens
EP0588750A3 (en) * 1992-08-05 1995-01-11 Cigb Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv.
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
US5618922A (en) 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
ES2528738T3 (en) * 2003-02-20 2015-02-12 The Chemo-Sero-Therapeutic Research Institute Method to enhance the efficacy of a preparation of a monoclonal antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755457A (en) * 1985-02-05 1988-07-05 Robert Guroff Marjorie Method for detecting HTLV-III neutralizing antibodies in sera
JP2520464B2 (en) * 1987-05-29 1996-07-31 タノツクス・バイオシステムズ・インコーポレーテツド Monoclonal antibody that neutralizes HIV-1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
JPH04502760A (en) * 1988-10-03 1992-05-21 レプリゲン・コーポレーション Novel HIV proteins and peptides effective in the diagnosis, prevention and treatment of AIDS
WO1991006575A1 (en) * 1989-11-03 1991-05-16 Repligen Corporation Hiv-1 specific human monoclonal antibody

Also Published As

Publication number Publication date
PT94276A (en) 1991-02-08
WO1990015078A1 (en) 1990-12-13
JPH05506561A (en) 1993-09-30
AU6036690A (en) 1991-01-07
EP0478689A1 (en) 1992-04-08
CA2058630A1 (en) 1990-12-06
EP0478689A4 (en) 1993-06-16

Similar Documents

Publication Publication Date Title
EP0777497A4 (en) Human neutralizing monoclonal antibodies to human immunodeficiency virus
GB8905669D0 (en) Modified antibodies
GB2196634B (en) Monoclonal antibodies to hiv and related peptides
GB2186592B (en) Cross-protective human monoclonal antibody compositions
GB8608068D0 (en) Monoclonal antibodies
IL94624A0 (en) Human monoclonal antibodies to hiv-1 mn qq120
GB8624899D0 (en) Monoclonal antibodies
GB8621910D0 (en) Monoclonal antibodies
GB8715347D0 (en) Monoclonal antibodies
EP0418347A4 (en) Human monoclonal antibodies to human immunodeficiency virus
GB8616174D0 (en) Monoclonal antibodies
IL83342A0 (en) Monoclonal antibodies,their preparation and their use
IL86960A0 (en) Preparation of human monoclonal antibodies
ZA903492B (en) T-lymphotropic retrovirus monoclonal antibodies
ZA904305B (en) Human monoclonal antibodies to hiv-1 mn gp 120
GB8610203D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
EP0407586A4 (en) Human monoclonal antibody and process for its preparation
IE902008L (en) HUMAN MONOCLONAL ANTIBODIES TO HIV-IMN gp120
IE891095L (en) Human monoclonal antibodies
GB9318912D0 (en) Humanised antibodies
ZA87863B (en) Cross-protective human monoclonal antibody compositions
IE891298L (en) Monoclonal antibodies
IE890064L (en) Monoclonal antibodies
GB2215725B (en) Monoclonal antibodies